All News

Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.

Under terms of the deal, Merck will provide an upfront payment of $30 million, with potential milestone payments of up to $1.3 billion for the Yale University spinout that develops targeted therapies for cancer.

Abrysvo had previously been approved for adults 60-years and older.

Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.

The current phase of the campaign is focused on family conversations during holiday gatherings.

The meeting is set to focus on advancing smoking cessation.

Under terms of the deal, Sanofi would sell a 50% controlling stake in Opella to CD&R, while remaining a significant shareholder.

The expanded indication of Selarsdi for the treatment of diseases such as psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn disease is expected to support the official launch early next year.

The gallery will be presented at the HLTH 2024 conference.

Regulatory action marks the fourth aesthetic indication and the first beyond facial treatments for Botox.

Vyloy is the first CLDN18.2-targeted therapy for advanced gastric and gastroesophageal junction adenocarcinoma to be approved in the United States.

People suffering from the condition reportedly struggle to find public restrooms in emergencies.

The study, released by Otsuka, reveals that caregivers perform the work of highly paid professionals.

Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.

Expanded approval of Lumryz offers a once-nightly treatment option for younger patients, eliminating the need for traditional narcolepsy treatments that often require multiple doses throughout the night.

The company includes the technology in drug development, improving efficiency, and other areas.

Sun Life U.S. teamed up with several other Florida-based companies to provide needed assistance in areas impacted by the recent storms.

Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue.

Vyalev is the first and only FDA-approved subcutaneous 24-hour infusion of a levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson disease.

The organization hopes to collect data to provide better education around Thrombosis.

Dr. Sandra Lee is joining the educational program, which originally launched last year.

Results from the Phase II/III Vibrance-MG study found that patients with generalized myasthenia gravis who were treated with nipocalimab plus standard-of-care achieved sustained disease control.

Results from the Phase III Vivid-1 trial found that more Crohn disease patients treated with mirikizumab achieved histologic response at week 52 compared to ustekinumab.

Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.

As part of the collaboration, Exelixis and Merck will evaluate zanzalintinib in combination with Keytruda for head and neck cancer.

Expanded indication of Bimzelx offers a prefilled syringe with a single 2 mL subcutaneous injection, improving upon the previous regimen of two 1 mL injections.

S-HiCon can reportedly achieve stable liquid formulation for over 200 mg/mL subcutaneous administration.

MedHub has been expanded to work with a wider variety of insurance plans.